AirNexis Therapeutics
AirNexis Therapeutics develops medicines for pulmonary diseases, led by the investigational COPD candidate AN01.
$200MSeries A
Role not disclosedLS
Life Sciences at Goldman Sachs Alternatives
Activity from announced rounds
Activity in this selectionbelvedere-trading-f14c94b7
- Rounds participated in
- 1
- Confirmed lead rounds
- — 1 roles undisclosed
- New companies
- 1 First participation on record · 0 follow-on
- Funding in participating rounds
- $200M 1 disclosed · full round size, not this investor’s share